Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6681)

VOLUNTARY ANNOUNCEMENT
ENTERING INTO COGNITIVE DIGITAL THERAPEUTICS COOPERATION AGREEMENT

This announcement is made by BrainAurora Medical Technology Limited 脑动极光医疗科技有限公司 (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis for the purposes of keeping the investors informed of the latest update on the business developments of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that Zhejiang BrainAurora Medical Technology Co., Ltd.* (浙江腦動極光醫療科技有限公司) ("**BrainAurora Zhejiang**"), an indirect wholly-owned subsidiary of the Company, has formally entered into the Cognitive Digital Therapeutics Cooperation Agreement (the "**Project**") with Beijing Jianguo Medical Technology Co., Ltd.* (北京健國醫療科技有限公司) ("**Beijing Jianguo Medical**"). Both parties will engage in deep collaboration from January 1, 2026 to December 30, 2026, focusing on the topic of "Construction and Promotion of Application Scenarios for Cognitive Function Assessment and Training in Mental Health", jointly facilitating the standardization, scalability and accessibility of cognitive impairment digital therapeutics (the "**Cooperation**").

BACKGROUND INTRODUCTION AND OVERALL OBJECTIVES OF THE PROJECT

Beijing Jianguo Technology Group, the parent company of Beijing Jianguo Medical founded in 1994, is a nationally recognized enterprise technology center with over 4,800 employees and a nationwide network covering R&D, production, and services. Leveraging Beijing Jianguo Technology Group's solid industrial foundation and rich project management experience in high-end medical technologies, Beijing Jianguo Medical focuses on the clinical translation and promotion of rehabilitation medical technologies. The Cooperation represents a practical initiative to integrate cutting-edge digital diagnosis and treatment algorithms with a mature industrialization system, aiming to jointly promote the standardized application and large-scale implementation of cognitive impairment digital therapeutics.

With cognitive function assessment and training as the entry point, the Project focuses on the practical challenges in China's mental health and social welfare systems, such as insufficient service capabilities for cognitive impairment and inconsistent technical pathways. It aims to gradually develop a replicable and scalable application model for digital therapeutics through the formulation of national standards, guidance from scientific research projects, and multi-scenario application validation, so as to provide services for a broader user base.

MAIN CONTENT OF THE COOPERATION

1. National standard research: Jointly develop a core technical indicator system, clinical validation pathway and application specifications for cognitive impairment digital therapy, providing evidence-based data and draft texts for the national standard establishment.

2. Multi-center pilot program: Simultaneously launch the "BrainAurora Cognitive Function Assessment and Training System" in mental health welfare institutions and communities in Hangzhou, Nanning, Wuhan, Mudanjiang and other regions. It is expected to cover 80% of target institutions and form a replicable intervention pathway.

3. Research project: Establish a long-term research cohort across institutions, regions and scenarios. All data will be jointly owned by the project implementation party and Zhejiang BrainAurora, to be used for subsequent policy formulation, technology upgrading and standard iteration.

REASONS FOR AND BENEFITS OF THE COOPERATION

The Cooperation represents another important initiative by the Company in the application, implementation and ecosystem construction of cognitive impairment digital therapy, following the participation in national major science and technology projects and the approval of the Cognitive Impairment Digital Therapy Key Laboratory of Beijing. Specifically, the Cooperation will:

1. Deepen technical exploration and commercialization in the field of mental health: Through cooperation with the project executor of the national-level research center, the Company will delve into the specific application scenario of mental health, exploring and validating innovative models for digital therapy in assessment, training, and management pathways. This will facilitate the deep integration of cutting-edge artificial intelligence algorithms with actual clinical needs, fostering more precise and universally applicable technological products and expanding the application boundaries of digital therapy in the field of mental health.

2. Promote industry standard establishment and market standardization: Participation in national standard research and multi-center sample validation will not only help accumulate high-level evidence-based medical evidence but also enable direct involvement in shaping industry standards. This will enhance the industry recognition and authority of the Company's solutions, laying a solid foundation for the large-scale nationwide promotion of its products.

3. Expand accessible service networks and social impact: The Project focuses on mental health welfare institutions and community settings, aiming to enhance cognitive impairment service capabilities at the grassroots level and within specific institutions. Successful implementation will significantly expand the coverage of the Company's products and services, particularly increasing penetration within public health and social welfare systems. This will create substantial social benefits while opening up new market growth opportunities.

4. Strengthen industry-research collaboration and data asset accumulation: The collaboration with Beijing Jianguo Medical further consolidates the Company's cooperative network with national-level scientific research institutions. The real-world data obtained from jointly establishing long-term research cohorts will become a valuable asset driving the iteration of the Company's algorithms, product optimization, and innovative R&D.

The Project and the Cooperation are in the initial execution stage. Actual progress and outcomes may be influenced by various factors including the research process, clinical validation, policy environment, and market acceptance. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's securities.

By order of the Board
BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
Mr. Tan Zheng
Chairman and Executive Director

Hong Kong, January 4, 2026

As of the date of this announcement, the Board comprises: (i) Mr. Tan Zheng as executive director; (ii) Mr. Li Sirui, Ms. Li Mingqiu and Mr. Deng Feng as non-executive directors; and (iii) Mr. Lam Yiu Por, Dr. Duan Tao and Mr. Tu Lei as independent non-executive directors.

* *English names are for identification purpose only.*